SEC Comment Letter for AXIM BIOTECHNOLOGIES, INC. (AXIM) (CIK 0001514946) (AXIM) — Jan 10, 2020
AXIM BIOTECHNOLOGIES, INC. (AXIM) (CIK 0001514946)
Date: Jan. 10, 2020 · CIK: 0001514946 · Accession: 0000000000-20-000250
AI Filing Summary & Sentiment
File numbers found in text: 000-54296
Letter
January 9, 2020 Robert Malasek Chief Financial Officer AXIM Biotechnologies, Inc. 45 Rockefeller Plaza 20th Floor, Suite 83 New York, NY 10111 Re:AXIM Biotechnologies, Inc. Form 10-K for the Fiscal Year Ended December 31, 2018 Filed April 8, 2019 File No. 000-54296 Dear Mr. Malasek: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
January 9, 2020
Robert Malasek
Chief Financial Officer
AXIM Biotechnologies, Inc.
45 Rockefeller Plaza
20th Floor, Suite 83
New York, NY 10111
Re:AXIM Biotechnologies, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2018
Filed April 8, 2019
File No. 000-54296
Dear Mr. Malasek:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences